Natacha Comandante-Lou

Natacha Comandante-Lou

Auto-generated profile, based on publicly available information

Natacha Comandante-Lou

Columbia University Irving Medical Center

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2020 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
NCNatacha Comandante-Lou
Natacha Comandante-Lou
MKMehwish Khaliq
Mehwish Khaliq
DVDivya Venkat
Divya Venkat
MMMohan Manikkam
Mohan Manikkam
MFMohammad Fallahi-Sichani
Mohammad Fallahi-Sichani
Cell-to-cell variability generates subpopulations of drug-tolerant cells that diminish the efficacy of cancer drugs. Efficacious combination therapies are thus needed to block drug-tolerant cells via minimizing the impact of heterogeneity. Probabilistic models such as Bliss independence have been developed to evaluate drug interactions and their combination efficacy based on probabilities of specific actions mediated by drugs individually and in combination. In practice, however, these models are often applied to conventional dose-response curves in which a normalized parameter with a value between zero and one, generally referred to as fraction of cells affected (fa), is used to evaluate the efficacy of drugs and their combined interactions. We use basic probability theory, computer simulations, time-lapse live cell microscopy, and single-cell analysis to show that fa metrics may bias our assessment of drug efficacy and combination effectiveness. This bias may be corrected when dynamic probabilities of drug-induced phenotypic events, i.e. induction of cell death and inhibition of division, at a single-cell level are used as metrics to assess drug efficacy. Probabilistic phenotype metrics offer the following three benefits. First, in contrast to the commonly used fa metrics, they directly represent probabilities of drug action in a cell population. Therefore, they deconvolve differential degrees of drug effect on tumor cell killing versus inhibition of cell division, which may not be correlated for many drugs. Second, they increase the sensitivity of short-term drug response assays to cell-to-cell heterogeneities and the presence of drug-tolerant subpopulations. Third, their probabilistic nature allows them to be used directly in unbiased evaluation of synergistic efficacy in drug combinations using probabilistic models such as Bliss independence. Altogether, we envision that probabilistic analysis of single-cell phenotypes complements currently available assays via improving our understanding of heterogeneity in drug response, thereby facilitating the discovery of more efficacious combination therapies to block drug-tolerant cells. Resistance to therapy due to tumor cell heterogeneity poses a major challenge to the use of cancer drugs. Cell-to-cell variability generates subpopulations of drug-tolerant cells that diminish therapeutic efficacy, even in populations of cells that are scored as highly sensitive based on drug potency. Overcoming such heterogeneity and blocking subpopulations of drug-tolerant cells motivate efforts toward identifying efficacious combination therapies. The success of these efforts depends on our ability to distinguish how heterogeneous populations of cells respond to individual drugs, and how these responses are influenced by combined drug interactions. In this paper, we propose mathematical and experimental frameworks to evaluate time-dependent drug interactions based on probabilistic metrics that quantify drug-induced tumor cell killing or inhibition of division at a single-cell level. These metrics can reveal heterogeneous drug responses and their changes with time and drug combinations. Thus, they have important implications for designing efficacious combination therapies, especially those designed to block or overcome drug-tolerant subpopulations of cancer cells.

25 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
NCNatacha Comandante-Lou
Natacha Comandante-Lou
TLTsering Lama
Tsering Lama
KCKevin Chen
Kevin Chen
JZJinglong Zhang
Jinglong Zhang
BHBin Hu
Bin Hu
PJPhilip L. De Jager
Philip L. De Jager
Diverse cellular states have been mapped in Alzheimer’s disease (AD) pathology, but their links to cognitive decline and the tissue signals driving their emergence remain unclear. We assembled a unified single-nucleus atlas from 867 diverse brains. Meta-analysis identified new cell-state associations with AD and prioritized a non-canonical reactive SLC38A2 high SMTN high CACNA1D high astrocyte (Ast10) as a key link between neuropathologies and cognitive decline. To identify regulators of Ast10 emergence, we modeled ligand-receptor relationships. Independent datasets and two spatial modalities validated these drivers and revealed Ast10’s multifocal distribution throughout the neocortex. Mechanistic validation in mouse and human astrocytes confirmed PLXNB1 , JAM2 and SEMA4D as regulators. In cerebrospinal fluid from a SEMA4D-blocking antibody trial, Ast10 markers are pharmacologically modifiable, and their reduction tracks with cognitive stabilization. Ast10 may contribute to cognitive decline through disrupted presynaptic neurotransmitter release and may be a convergence point for AD and other neurodegenerative pathologies, a promising target for enhancing resilience to dementia.

6 February 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
VHVerena Haage
Verena Haage
JTJohn F. Tuddenham
John F. Tuddenham
NCNatacha Comandante-Lou
Natacha Comandante-Lou
ABAlex Bautista
Alex Bautista
AMAnna Monzel
Anna Monzel
PJPhilip L. De Jager
Philip L. De Jager
: While efforts to identify microglial subtypes have recently accelerated, the relation of transcriptomically defined states to function has been largely limited to in silico annotations. Here, we characterize a set of pharmacological compounds that have been proposed to polarize human microglia towards two distinct states – one enriched for AD and MS genes and another characterized by increased expression of antigen presentation genes. Using different model systems including HMC3 cells, iPSC-derived microglia and cerebral organoids, we characterize the effect of these compounds in mimicking human microglial subtypes in vitro . We show that the Topoisomerase I inhibitor Camptothecin induces a CD74 high /MHC high microglial subtype which is specialized in amyloid beta phagocytosis. Camptothecin suppressed amyloid toxicity and restored microglia back to their homeostatic state in a zebrafish amyloid model. Our work provides avenues to recapitulate human microglial subtypes in vitro , enabling functional characterization and providing a foundation for modulating human microglia in vivo .

12 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
VHVerena Haage
Verena Haage
JTJohn F. Tuddenham
John F. Tuddenham
ABAlex Bautista
Alex Bautista
CWCharles C. White
Charles C. White
FGFrankie Garcia
Frankie Garcia
PJPhilip L. De Jager
Philip L. De Jager
Disease-associated microglia (DAM), initially described in mouse models of neurodegenerative diseases, have been classified into two related states; starting from a TREM2-independent DAM1 state to a TREM2 dependent state termed DAM2, with each state being characterized by the expression of specific marker genes 1 . Recently, single-cell (sc)RNA-Seq studies have reported the existence of DAMs in humans 2–6 ; however, whether DAMs play beneficial or detrimental roles in the context of neurodegeneration is still under debate 7,8 . Here, we present a pharmacological approach to mimic human DAM in vitro by exposing different human microglia models to selected histone deacetylase (HDAC) inhibitors. We also provide an initial functional characterization of our model system, showing a specific increase of amyloid beta phagocytosis along with a reduction of MCP-1 secretion. Additionally, we report an increase in MITF expression, a transcription factor previously described to drive expression towards the DAM phenotype. We further identify CADM1 , LIPA and SCIN as DAM- marker genes shared across various proposed DAM signatures and in our model systems. Overall, our strategy for targeted microglial polarization bears great potential to further explore human DAM function and biology.

29 June 2026 in Nature Immunology
Verified
Journal Article
Closed access
AGAmy X. Guo
Amy X. Guo
TFTheodore M. Fisher
Theodore M. Fisher
NCNatacha Comandante-Lou
Natacha Comandante-Lou
PJPhilip L. De Jager
Philip L. De Jager
SLShane Liddelow
Shane Liddelow

21 September 2025 in bioRxiv
Verified
Preprint
Open access
ZAZachary M. Augur
Zachary M. Augur
GFGarrett M. Fogo
Garrett M. Fogo
CBCourtney R. Benoit
Courtney R. Benoit
GTGizem Terzioglu
Gizem Terzioglu
ZMZachary R. Murphy
Zachary R. Murphy
TYTracy L. Young-Pearse
Tracy L. Young-Pearse
Background: Bcl-2-associated athanogene 3 (BAG3) is a mediator of chaperone assisted selective autophagy, and in the brain, most highly expressed in astrocytes. However, its role in astrocytes remains poorly defined. Given the genetic and pathological links of BAG3 to proteostasis and neurodegenerative diseases, we investigated how BAG3 contributes to astrocyte function and Alzheimer’s disease (AD). Methods: SnRNA-seq of the human brain determined cell type expression of BAG3. CRISPR/Cas9 gene editing in human iPSCs, followed by tandem mass tag-mass spectrometry and RNA-sequencing was performed to assess proteomic and transcriptomic changes following BAG3 loss. Co-immunoprecipitation of BAG3 in human astrocytes defined the interactome, with top interactors being validated by western blot (WB), AlphaFold modeling, and proximity ligation assays. In astrocytes, autophagic flux, lysosomal phenotypes, proteasome activity, and endocytic uptake were measured in BAG3 KO and BAG3 WT. Finally, BAG3 expression was assessed in postmortem AD brain by WB and snRNA-seq, and its functional relevance to amyloid-β (Aβ) degradation was tested in co-cultures of BAG3 KO iAs with familial AD neurons. Results: In human brain and iPSC models, BAG3 was most highly expressed in astrocytes. Further, BAG3 loss caused greater proteomic disruption in astrocytes than in neurons. In the absence of BAG3, astrocytes showed reduced autophagy, diminished lysosome abundance and activity, and decreased proteasome function. To uncover molecular binding partners of BAG3 that might influence these phenotypes, we performed co-immunoprecipitation, revealing interactions with HSPB8 and other heat shock proteins, proteasome regulators (PSMD5, PSMF1), and the retromer component, VPS35. Integration of BAG3 KO transcriptomic and proteomic datasets pinpointed AD-relevant proteins under post-translational control of BAG3, which included GFAP, BIN1, and HSPB8. HSPB8 levels were markedly reduced in BAG3-deficient astrocytes with overexpression partially rescuing its levels. Loss of astrocytic BAG3 impaired Aβ clearance in co-culture with APP/PSEN1 mutant neurons, directly linking BAG3 to a disease-relevant astrocyte function. Finally, analysis of postmortem brain tissue revealed BAG3 marks a stress-responsive astrocyte subtype in the brain of aged individuals with AD. Conclusions: BAG3 binds to key regulators of autophagy, proteasome activity, and retromer function to coordinate astrocyte proteostasis, lysosomal function, and Aβ clearance. These findings position BAG3 as a potential therapeutic target and coordinator of glial protein quality control in neurodegeneration.